appropriate endpoints in clinical trials and markers for long-term clinical outcome
TRANSCRIPT
![Page 1: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/1.jpg)
Appropriate Endpoints in Clinical Trials and Markers for
Long-Term Clinical OutcomeAntonio C. Wolff, MD, FACP
Associate Professor of Oncology
![Page 2: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/2.jpg)
Alternative Title
“How to Upset Statisticians and Methodologists in Less
Than 20 Minutes”
![Page 3: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/3.jpg)
Goals of Preoperative Systemic Therapy in Operable Breast Cancer
• To improve odds of breast conservation surgeryYES, BCS rates improved by 5-10%
• To allow early assessment of treatment effectYES, but what does it truly mean in the long run?What are the optimal markers for various phenotypes ?What is the true outcome of interest?
• To allow therapy adjustments to improve outcomeNOT THERE YET …When to do it, how to determine the need, and change to what?
What Is The Clinical Utility of PST?
![Page 4: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/4.jpg)
Goals of Preoperative Systemic Therapy in Operable Breast Cancer
• PST may allow trials that target various breast cancer subtypes and that rely on robust surrogate markers for the outcome of interest
Smaller, faster, and more informative trialsMore efficient use of resources …
That’s What UltimatelyBrought Us Here Today!
![Page 5: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/5.jpg)
What is a Surrogate Outcome?
• A surrogate outcome should be in the causal pathway of true outcome – Replaces a distal endpoint (e.g., survival) by
a proxy endpoint (e.g., clinical or pathologic response, imaging, gene expression, …)
• Surrogate marker– A measure of the surrogate outcome
![Page 6: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/6.jpg)
• A method or assay used to measure a surrogate marker has been standardized– Including pre-analytical variables
• A method or assay is reproducible whenever/wherever used– Central site gene expression profiles– Locally pathology assessment
ER/PR and HER2
What is a Reliable (Robust) Measure?Basic Assumptions
![Page 7: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/7.jpg)
What is a Surrogate Marker?
• Defining Characteristic:– A marker must predict clinical outcome, in
addition to predicting the effect of treatment on clinical outcome
Marker ClinicalOutcome
Adapted from E. Garrett-Mayer, PhD
![Page 8: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/8.jpg)
What is a Surrogate Marker?
• Operational Definition:– Establish an association between marker
and clinical outcome– Establish an association between marker,
treatment, and clinical outcome, in which marker mediates relationship between clinical outcome and treatment
Marker ClinicalOutcomeTreatment
Adapted from E. Garrett-Mayer, PhD
![Page 9: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/9.jpg)
Marker ClinicalOutcomeTreatment
Marker
ClinicalOutcome
Treatment ?
Is a Correlate MarkerAlso a Surrogate Marker?
![Page 10: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/10.jpg)
Not all Markers Are Appropriate for This Role …
Marker ClinicalOutcomeTreatment
Alopecia
Response
Treatment NO!
![Page 11: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/11.jpg)
Surrogate Markers and PST
.CHEMO
.ENDOCRINE
.ANTI-HER2, …
Marker ClinicalOutcomeTreatment
.RESPONSE- clinical or path.MOLECULAR- proliferation, cell death, gene expression, epigenetics, circulating tumor cells, etc ….IMAGING- US, PET, MRI
.LOCAL CONTROL
.SURVIVAL
during/after Rx
![Page 12: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/12.jpg)
Surrogate Markers and PST
.CHEMO
.ENDOCRINE
.ANTI-HER2, …
Marker ClinicalOutcomeTreatment
.RESPONSE- clinical or path.MOLECULAR- proliferation, cell death, gene expression, epigenetics, circulating tumor cell, etc ….IMAGING- US, PET, MRI
.LOCAL CONTROL
.SURVIVAL
during/after Rx
![Page 13: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/13.jpg)
pCR SurvivalAnthracycline± taxane PST
Kaplan-Meier survival curves according to pathologic response in the breast at surgery
NSABP B-27OS
Bear et al. J Clin Oncol; 24:2019, 2006
Is pCR a Surrogate for Survival?
DFS
![Page 14: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/14.jpg)
PST, pCR, and Survival• Doubling of pCR with addition of docetaxel in
NSABP B-27 did not result in improved survival– At least, not until this morning!
• Improved survival not limited to a pCR subset– Path response is a continuous variable, not “all or none”– The role of pathology response as a surrogate for
survival can be refined by the use of standardized pathology measures after PST
• E.g., Residual Cancer Burden (Symmans, ASCO 2006)AJCC TNM after PST (Carey, JNCI 2005)
![Page 15: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/15.jpg)
How to Determine if a Markeris Useful as a Surrogate?
Marker ClinicalOutcomeTreatment
during/after Rx
Marker
ClinicalOutcomeTreatment
predictive ability?
during/after Rx
frequency?
![Page 16: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/16.jpg)
pCR
Survival
70%
15%
Inv Ductal(n = 770)
93%5y OS
3%pCR
Inv Lobular(n = 118)
Cristofanilli, JCO 2005
Anthracycline± taxane PST
.Absence of pCR - okPresence of pCR - ?
Is pCR a Useful Surrogate inInvasive Lobular Cancer After Chemo?
![Page 17: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/17.jpg)
Is pCR a Useful Surrogate inER-Positive Disease After Chemo?
96%84%5y OS
8%24%pCR
ER-posER-negGuarneri,JCO 2006
.Absence of pCR – truly ok?Presence of pCR – helps more?
Anthracycline± taxane PST
pCR
Survival
No
Yes
![Page 18: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/18.jpg)
Is pCR a Surrogate for Survivalin ER-pos Versus ER-neg Disease?
84%
83%
pCR24%
84%
65%
No pCR92%
ER posER negn = 1731Stage I-IIIAnthracycline-based PST(66% had taxane)
96%67%5y OS(HR 0.36)
91%50%5y PFS
pCR8%
No pCR76%
Guarneri et al. J Clin Oncol; 24:1037, 2006
![Page 19: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/19.jpg)
Surrogate Markers and PST
.CHEMO
.ENDOCRINE
.ANTI-HER2, …
SurrogateMarker
.RESPONSE- clinical or path.MOLECULAR- proliferation, cell death, gene expression, epigenetics, circulating tumor cells ….IMAGING- US, PET, MRI
.LOCAL CONTROL
.SURVIVAL
ClinicalOutcome
during/after Rx
Treatment
![Page 20: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/20.jpg)
.CHEMO
.ENDOCRINE
.ANTI-HER2, …
Treatment
.RESPONSE- clinical or path.MOLECULAR- proliferation, cell death, gene expression, epigenetics, circulating tumor cells ….IMAGING- US, PET, MRI
.LOCAL CONTROL
.SURVIVAL
ClinicalOutcome
Lessons from the Adjuvant Setting?
SurrogateMarker
during/after Rx
![Page 21: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/21.jpg)
Breast Cancer is a Mosaic!
.CHEMO
.ENDOCRINE
.ANTI-HER2, …
PredictiveMarker Treatment
.TUMOR FEATURES- gene expression- ER, PR, HER2- pharmacogenetics- various nomograms
.LOCAL CONTROL
.SURVIVAL
ClinicalOutcome
baseline
![Page 22: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/22.jpg)
Identification of Tumor Subtypes
Treatment ClinicalOutcome
PredictiveMarker
Selection of Patient Populationfor Various Therapy Options is Key!
baseline
![Page 23: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/23.jpg)
Marker for Therapy Selection
Treatment ClinicalOutcome
PredictiveMarker
ClinicalOutcomeTreatment
SurrogateMarker(same or
2nd marker)
PredictiveMarker
ClinicalOutcomeTreatment
SurrogateMarker(same or
2nd marker)
PredictiveMarkerbaseline
baseline
baseline
OR
![Page 24: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/24.jpg)
ER pos SurvivalEndocrine Rx
pCR
HER2 pos SurvivalTrastuzumab
pCR
Timing of Observation Matters!
?
.Are we looking too soon?
.pCR rate high (and early)
.Will it correlate with survival?
?
![Page 25: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/25.jpg)
Timing of Observation Matters!
HER2 pos SurvivalTrastuzumab pCR
ER pos SurvivalEndocrine Rx
pCR ?.Are we looking too soon?
.pCR rate high (and early)
.Will it correlate with survival? It may ….
![Page 26: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/26.jpg)
Marker TrueOutcomeTreatment
Marker SurrogateOutcomeTreatment
What if Surrogate Outcome TrulyCorrelates with True Outcome?
?
![Page 27: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/27.jpg)
Marker SurvivalTreatment
pCR
Surrogate Itself Then Becomes the “Endpoint” …
Marker Treatment
![Page 28: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/28.jpg)
pCRTreatmentSurrogate
Marker(same or
2nd marker)
Marker pCRTreatmentSurrogate
Marker(same or
2nd marker)
… And The Search Then Begins fora “Surrogate” for the Surrogate!
Marker
??
![Page 29: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/29.jpg)
Marker Utility Trial Design
STARTSTARTTHERAPYTHERAPY
Mar
ker
at B
aseline GoodGood
ResultResult
BadBadResultResult
OutcomeOutcomeAssessmentAssessment
TREATMENTTREATMENTDECISIONDECISION
Mar
ker
at M
idM
arke
r at
Mid-- P
oint
Point
.Assumes that you have a good marker
.Assumes that you have a good 2nd therapy!
![Page 30: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/30.jpg)
For Post-Operative Decisions …
STARTSTARTTHERAPYTHERAPY
Mar
ker
at B
aseline GoodGood
ResultResult
BadBadResultResult
SurvivalSurvival
SAME Rx?SAME Rx?
DIFFERENT Rx?DIFFERENT Rx?
No More Rx?No More Rx?
Surg
ical A
sses
smen
tSu
rgical A
sses
smen
t
![Page 31: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/31.jpg)
For Preoperative Decisions …
STARTSTARTTHERAPYTHERAPY
Mar
ker
at B
aseline
Mar
ker
at M
idM
arke
r at
Mid-- P
oint
Point
GoodGoodResultResult
BadBadResultResult
Surg
ical A
sses
smen
tSu
rgical A
sses
smen
t
SAME Rx?SAME Rx?
DIFFERENT Rx?DIFFERENT Rx?
STOP Rx?STOP Rx?
.Is the prognostic utility of pCR differentif achieved after therapy x, 2x, or x+y therapy?
![Page 32: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/32.jpg)
Take Home Messages
• Surrogate markers are affected by:– Population (tumor subtypes)– Intervention (therapy of interest)– Timing of assessment (depends on therapy
and on tumor subtype)– Endpoint (survival is the gold standard)
![Page 33: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/33.jpg)
Take Home Messages
• Surrogate markers are affected by:– Population (tumor subtypes)– Intervention (therapy of interest)– Timing of assessment (depends on therapy
and on tumor subtype)– Endpoint (survival is the gold standard)
• Predictive markers at baseline are more critical than intermediate surrogate markers … at least right now
![Page 34: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/34.jpg)
Unequivocally Yes!
But, it depends …
Is pCR a Useful Surrogate Marker?
![Page 35: Appropriate Endpoints in Clinical Trials and Markers for Long-Term Clinical Outcome](https://reader031.vdocuments.us/reader031/viewer/2022021022/6204ec824c89d3190e0c949d/html5/thumbnails/35.jpg)
Thank you!I think …